Claims
- 1. A compound according to the chemical structure:
- 2. The compound according to claim 1 wherein n is 1 to 8.
- 3. The compound according to claim 1 wherein said compound has the structure:
- 4. The compound according to claim 3 where one of X1, X2 and X3 is F and the other of X1, X2 and X3 is H.
- 5. The compound according to claim 4 wherein R6 is
- 6. The compound according to claim 5 wherein m is 1-2, n is 1-2, RA is CH3 and RB is CH2CH2OH.
- 7. The compound according to claim 6 wherein m is 1 and n is 2.
- 8. The compound according to claim 3 wherein R6 is
- 9. The compound according to claim 8 wherein RA is CH3 and RB is CH2CH2OH.
- 10. The compound according to claim 3 wherein R6 is
- 11. The compound according to claim 10 wherein R is a C3-C6 alkylene ester group.
- 12. The compound according to claim 11 wherein X1, X2 and X3 are H.
- 13. The compound according to claim 1 wherein said chemical structure is
- 14. The compound according to claim 13 wherein R5 is H.
- 15. A pharmaceutical composition comprising an effective amount of a compound according to the chemical structure:
- 16. The composition according to claim 15 wherein n is 1 to 8.
- 17. The composition according to claim 15 wherein said compound has the structure:
- 18. The composition according to claim 17 where one of X1, X2 and X3 is F and the other of X1, X2 and X3 is H.
- 19. The composition according to claim 18 wherein R6 is
- 20. The composition according to claim 19 wherein m is 1-2, n is 1-2, RA is CH3 and RB is CH2CH2OH.
- 21. The composition according to claim 20 wherein m is 1 and n is 2.
- 22. The composition according to claim 17 wherein R6 is
- 23. The composition according to claim 22 wherein RA is CH3 and RB is CH2CH2OH.
- 24. The composition according to claim 17 wherein R6 is
- 25. The composition according to claim 24 wherein R is a C3-C6 alkylene ester group.
- 26. The composition according to claim 25 wherein X1, X2 and X3 are H.
- 27. The composition according to claim 15 wherein said chemical structure is
- 28. The composition according to claim 27 wherein R5 is H.
- 29. A method of treating a patient having a neurodegenerative condition or other neurological condition where acetylcholine transmission neurons and their target cells are affected comprising administering to said patient an effective amount of a compound according to the chemical structure:
- 30. The method according to claim 29 wherein n is 1 to 8.
- 31. The method according to claim 29 wherein said compound has the structure:
- 32. The method according to claim 31 where one of X1, X2 and X3 is F and the other of X1, X2 and X3 is H.
- 33. The method according to claim 32 wherein R6 is
- 34. The method according to claim 33 wherein m is 1-2, n is 1-2, RA is CH3 and RB is CH2CH2OH.
- 35. The method according to claim 34 wherein m is 1 and n is 2.
- 36. The method according to claim 31 wherein R6 is
- 37. The method according to claim 36 wherein RA is CH3 and RB is CH2CH2OH.
- 38. The method according to claim 31 wherein R6 is
- 39. The method according to claim 38 wherein R is a C3-C6 alkylene ester group.
- 40. The method according to claim 39 wherein X1, X2 and X3 are H.
- 41. The method according to claim 28 wherein said chemical structure is
- 42. The method according to claim 41 wherein R5 is H.
- 43. The method according to claim 29 wherein said condition is selected from the group consisting of Parkinson's disease, Huntington disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease, dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke.
- 44. The method according to claim 31 wherein said condition is selected from the group consisting of Parkinson's disease, Huntington disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease, dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke.
- 45. The method according to claim 34 wherein said condition is selected from the group consisting of Parkinson's disease, Huntington disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease, dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke.
- 46. The method according to claim 38 wherein said condition is selected from the group consisting of Parkinson's disease, Huntington disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease, dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke.
- 47. The method according to claim 39 wherein said condition is selected from the group consisting of Parkinson's disease, Huntington disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedrich's ataxia, Pick's disease, Bassen-Kornzweig syndrome, Refsom's disease, retinal degeneration, Cruetzfelt-Jacob syndrome or prion disease, dementia with Lewy bodies, schizophrenia, paraneoplastic cerebellar degeneration and neurodegenerative conditions caused by stroke.
RELATED APPLICATIONS
[0001] This application claims from provisional application serial number 60/306,585, filed Jul. 19, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60306585 |
Jul 2001 |
US |